Close Menu

NEW YORK (GenomeWeb) – With a series of recent collaborations, German biomarker firm Protagen is shifting its focus to cancer immunotherapy.

Over the last year the company has signed agreements with the German National Center for Tumor Diseases, the National Cancer Institute, and the Gustave Roussy Institute of Oncology for biomarker work in immunoncology, with a specific focus on identifying patients at risk of immune-related adverse events (irAEs).

"This is the major focus of the company and has been for the last 16 months," said Georg Lautscham, Protagen's CBO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.